Companies / Czech Republic
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
Maturing Market Forces Forecast Up
March 2007 | Industry ForecastSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
BMI has upwardly revised its forecast for the Czech Republic pharmaceutical market after the country introduced a new decree that will increase the provision of modern and therefore expensive medicines. While this development will benefit patients and multinational drugmakers, local pharmaceutical firms such as Zentiva will suffer because it produces relatively expensive generic medicines that will no longer be covered by insurance. We now expect the value of the Czech Republic pharmaceutical market to reach US$4.05bn by 2011, up marginally from BMI's previous forecast of US$3.96bn.